News

The payment triggered by Novartis filing of the necessary documentation to initiate a Phase 1 clinical trial with a HuCAL-derived fully human antibody.

Molecules that selectively interfere with protein production can stop human cells from making the abnormal molecules that cause Huntington’s disease.

Scientists develop a mathematical model to predict optimal time for loading and unloading cryoprotectants.

The Proteome Research Centre at UCD Conway Institute will demonstrate the Stabilizor technology to other potential customers and gain early access to new products.

Company provides instruments, reagents and related components to support laboratories’ efforts in flu detection and nucleic acid sequencing.

Government and private sector cancer scientists have launched a research partnership to find biomarkers for lung cancer that develops in people who have never smoked.

PerkinElmer’s LANCE® Ultra™ technology will be offered for use through Cerep’s drug candidates selection and qualification services.

Researchers discover a mechanism by which several viruses suppress aspects of the cell to stabilize their nucleic acids to promote an efficient infection.

Under the terms of the agreement, TheraCode GmbH will pay Jerini AG a purchase price of approximately € 5 million in cash.

Company’s Recombumin and albucult products are claimed to be the first to comply with the new excipient monograph standard for recombinant human albumin.